The Zhitong Finance App learned that Damo released a research report stating that it gave Minimally Invasive Healthcare (00853) a “synchronized with the market” rating, and its net loss forecast for this year and next two years was reduced by 4.8% and 13.1%, respectively, while the net profit forecast for 2026 was also raised by 13.3%. Taking into account the streamlined pipeline, the 2027-2030 sales forecast was reduced by 3% to 7%, the earnings per share estimate was reduced by 3% to 14%, and the target price was raised from HK$8.4 to HK$9.

The bank said that after considering Minimally Invasive Healthcare's performance last year, it raised its total sales forecast for this year and next two years by 1.9% and 1.7%, respectively, to a year-on-year increase of 21.1% and 18.7%, which is generally in line with management guidelines. As management focuses on continuous R&D and reduction of operating expenses in the short term, it maintains the forecast that its net loss will narrow further this year and next two years, and it is expected that the loss will be turned into a profit in 2026.